Recursion Pharmaceuticals Chases Clinical Wins as Eli Lilly Builds Largest AI Supercomputer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 01 2026
0mins
Source: NASDAQ.COM
- AI Technology Potential: Recursion Pharmaceuticals boasts the largest AI supercomputer in the pharmaceutical industry aimed at accelerating drug development, which could yield substantial returns for investors if successful, yet it currently has no products on the market.
- Clinical Trial Challenges: Despite partnerships with pharmaceutical giants like Merck and Roche, Recursion's research has largely yielded empty results, highlighting significant challenges in achieving clinical trial success rates.
- Eli Lilly's Advantage: Eli Lilly has announced plans to build an even larger AI supercomputer, leveraging its extensive clinical trial data to train AI models, thereby gaining a competitive edge in drug discovery.
- Investment Risk Assessment: While Recursion may offer higher potential upside, it also carries greater risks, making Eli Lilly a safer investment choice for those uncomfortable with high volatility in the biotech sector.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1032.970
Low
950.00
Averages
1192
High
1500
Current: 1032.970
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
